Advances in design and development of ophthalmic drugs
Ophthalmic diseases, including glaucoma, age-related macular degeneration, diabetic retinopathy, and dry eye disease, are a significant public health concern, affecting millions of people worldwide. Despite the increasing availability of some effective treatments, there is still an unmet need for safe and even more effective drugs that can treat these conditions.
This Article Collection focuses on the latest advances in drug design and development for the treatment of various ophthalmic diseases and conditions. This Collection will provide a valuable resource for researchers, clinicians, and pharmaceutical companies working in the field of ophthalmic drug design and development and will further advance the understanding of the current state of the art in ophthalmic drug research and help pave the way for the development of safe and effective treatments for ophthalmic diseases.
Guest advisors
Dr. Georgios Panos(Nottingham University Hospitals)
Dr. Georgios D. Panos is a Consultant Ophthalmologist with a special interest in Vitreoretinal Surgery and Medical Retina at the Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, United Kingdom. His research is mainly focused on ocular pharmacology, retinal diseases, vitreoretinal and cataract surgery and ophthalmic imaging.